Katherine Donald

Katherine Donald

Auto-generated profile, based on publicly available information

Katherine Donald

Michael Smith Laboratories, University of British Columbia, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2023 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
TBTahereh Bozorgmehr
Tahereh Bozorgmehr
RBRozlyn C. T. Boutin
Rozlyn C. T. Boutin
SWSarah E. Woodward
Sarah E. Woodward
KDKatherine Donald
Katherine Donald
JCJo May Chow
Jo May Chow
BFB. Brett Finlay
B. Brett Finlay
Background. Studies suggest that early-life gut microbiota composition and intestinal short-chain fatty acids (SCFAs) are linked to future asthma susceptibility. Furthermore, infancy offers a critical time window to modulate the microbiota and associated metabolites through diet-microbe interactions to promote infant health. Human milk oligosaccharides (HMOs), nondigestible carbohydrates abundant in breast milk, are prebiotics selectively metabolized by gut microbiota that consequently modify microbiome composition and SCFA production. Methods. Using a house dust mite mouse model of allergy, we investigated the impacts of early oral treatment of pups with biologically relevant doses of 2-fucosyllactose (2-FL) and 6-sialyllactose (6-SL), two of the most abundant HMOs in human milk, in amelioration of allergic airway disease severity. Results. We found that administration of 2-FL and 6-SL during early life reduced lung histopathology scores, circulating IgE, cytokine levels, and inflammatory cell infiltration, all hallmark symptoms of allergic asthma. HMO supplementation also increased the relative abundance of intestinal Bacteroidetes and Clostridia, known SCFA producers within the gut. Indeed, we detected increased SCFA concentrations in both the intestine and blood of adult mice who received HMOs prior to weaning. Conclusion. We propose a model in which orally administered HMOs delivered during early life shift the microbiota toward increased production of SCFAs, which dampens the allergic immune responses behind allergy and asthma. Overall, these data suggest the potential for HMO supplementation to protect infants against asthma development later in life, with possible benefits against additional atopic diseases such as eczema and food allergies.

4 October 2024 in Cell Reports
Verified
Journal Article
Open access
KDKatherine Donald
Katherine Donald
ASAntonio Serapio-Palacios
Antonio Serapio-Palacios
ZGZachary Gerbec
Zachary Gerbec
TBTahereh Bozorgmehr
Tahereh Bozorgmehr
RHRavi Holani
Ravi Holani
BFB. Brett Finlay
B. Brett Finlay
Asthma susceptibility is linked to dysbiosis in early-life gut microbiota, and the antibody secretory immunoglobulin (Ig)A (SIgA) is a key determinant of gut microbiota composition. SIgA is obtained through breast milk during the critical early-life window. We use a mouse model of SIgA deficiency and the house dust mite (HDM) model of asthma to elucidate the role of maternal SIgA in modulating the early-life gut microbiota and asthma protection. Mice that do not receive maternal SIgA display a transient bloom of segmented filamentous bacteria (SFB) in the small intestine during the early post-weaning period. Mice that do not receive maternal SIgA also display elevated T helper type 17 (Th17) cell activation in the intestine, which persists into adulthood and is associated with more severe inflammation in response to the HDM model of asthma. This study demonstrates a mechanism by which breast-milk-derived SIgA influences immune development and asthma susceptibility by modulating the early-life gut microbiota.

17 December 2024 in Science Signaling
Verified
Journal Article
Closed access
RHRavi Holani
Ravi Holani
Haggai Bar-YosephHaggai Bar-Yoseph
Haggai Bar-Yoseph
ZKZakhar Krekhno
Zakhar Krekhno
ASAntonio Serapio-Palacios
Antonio Serapio-Palacios
KMKyung-Mee Moon
Kyung-Mee Moon
BFBarton Finlay
Barton Finlay
Bile acids (BAs) affect the growth of potentially pathogenic commensals, including those from the Enterobacteriaceae family, which are frequently overrepresented in inflammatory bowel disease (IBD). BAs are normally reabsorbed in the ileum for recycling and are often increased in the colonic lumina of patients with IBD, including those with Crohn’s disease (CD). Here, we investigated the influence of BAs on gut colonization by Enterobacteriaceae. We found increased abundance of Enterobacteriaceae in the colonic mucosae of patients with CD with a concomitant decrease in the transporters that resorb BAs in the ileum. The increase in Enterobacteriaceae colonization was greater in the colons of patients who had undergone terminal ileum resection compared with those with intact ileum, leading us to hypothesize that BAs promote intestinal colonization by Enterobacteriaceae. Exposure of human colonic epithelial cell lines to BAs reduced mitochondrial respiration, increased oxygen availability, and enhanced the epithelial adherence of several Enterobacteriaceae members. In a publicly available human dataset, mucosal Enterobacteriaceae was negatively associated with the expression of genes related to mitochondrial function. In a murine model, increased intestinal BA availability enhanced colonization by Escherichia coli in a manner that depended on bacterial respiration. Together, our findings demonstrate that BAs reduce mitochondrial respiration in the colon, leading to an increase in oxygen availability that facilitates Enterobacteriaceae colonization. This identification of BAs as facilitators of host-commensal interactions may be relevant to multiple intestinal diseases.